Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume $0.20 -0.13 (-39.39%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Citius Pharmaceuticals Short Interest DataCitius Pharmaceuticals (CTXR) has a short interest of 11.79 million shares. This marks a -5.07% decrease in short interest from the previous month. The short interest ratio (days to cover) is 10.5, indicating that it would take 10.5 days of the average trading volume of 1.47 million shares to cover all short positions.Current Short Interest11,790,000 sharesPrevious Short Interest12,420,000 sharesChange Vs. Previous Month-5.07%Dollar Volume Sold Short$4.39 millionShort Interest Ratio10.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares180,730,000 sharesPercentage of Shares Shorted6.52%Today's Trading Volume11,263,775 sharesAverage Trading Volume1,466,889 sharesToday's Volume Vs. Average768% Short Selling Citius Pharmaceuticals? Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTXR Short Interest Over TimeCTXR Days to Cover Over TimeCTXR Percentage of Float Shorted Over Time Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Citius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202411,790,000 shares $4.39 million -5.1%N/A10.5 $0.37 10/15/202412,420,000 shares $4.65 million -2.7%N/A8.9 $0.37 9/30/202412,770,000 shares $6.39 million +1.9%N/A7.2 $0.50 9/15/202412,530,000 shares $6.51 million -6.4%N/A5.8 $0.52 8/31/202413,390,000 shares $7.63 million +9.0%N/A6.3 $0.57 8/15/202412,280,000 shares $7.20 million -16.1%N/A5.5 $0.59 Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/202414,630,000 shares $13.24 million +21.9%N/A5.8 $0.91 7/15/202412,000,000 shares $9.18 million -15.2%N/A5.4 $0.77 6/30/202414,150,000 shares $8.26 million -8.5%N/A7.1 $0.58 6/15/202415,460,000 shares $9.67 million -2.8%N/A9.9 $0.63 5/31/202415,910,000 shares $11.10 million +9.9%N/A10.6 $0.70 5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62 4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75 4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77 3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90 3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74 2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77 2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84 1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62 1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75 12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76 12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80 11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77 11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77 10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75 10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70 9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68 9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76 8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91 8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86 7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99 7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19 6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20 6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26 5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16 5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28 4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45 4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64 3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17 3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15 2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23 1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39 1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12 12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79 12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13 11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17 11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07 10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08 10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08 9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21 9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23 8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23 8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27 7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89 7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91 6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92 6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95 5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94 5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90 4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01 4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55 3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79 3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58 2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54 2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63 1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51 1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53 12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54 12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70 11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69 11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81 10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87 10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09 9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03 9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03 8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25 8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81 7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89 7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92 6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48 6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23 5/28/202115,820,000 shares $36.07 million +8.6%12.9%2.5 $2.28 5/14/202114,570,000 shares $27.54 million +24.3%N/A1.7 $1.89 4/30/202111,720,000 shares $24.73 million -10.4%N/A0.8 $2.11 4/15/202113,080,000 shares $23.54 million +18.6%N/A0.9 $1.80 3/31/202111,030,000 shares $20.41 million +51.3%N/A0.8 $1.85 3/15/20217,290,000 shares $13.92 million -27.9%N/A0.6 $1.91 2/26/202110,110,000 shares $20.83 million +261.1%N/A0.9 $2.06 2/12/20212,800,000 shares $3.81 million +15.7%N/A0.3 $1.36Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 1/29/20212,420,000 shares $2.90 million +112.3%N/A1.6 $1.20 1/15/20211,140,000 shares $1.30 million -9.5%N/A1.4 $1.14 12/31/20201,260,000 shares $1.31 million -23.6%N/A1.8 $1.04 12/15/20201,650,000 shares $1.77 million +71.8%N/A2.2 $1.07 11/30/2020960,600 shares $947,824.02 -20.0%N/A1.2 $0.99 11/15/20201,200,000 shares $1.15 million -9.1%N/A1.6 $0.95 10/30/20201,320,000 shares $1.33 million +6.5%N/A1.6 $1.01 10/15/20201,240,000 shares $1.33 million +53.3%N/A1.1 $1.07 9/30/2020809,100 shares $841,464.00 +15.4%N/A0.6 $1.04 9/15/2020701,200 shares $743,272.00 -8.9%N/A0.2 $1.06 8/31/2020769,400 shares $715,542.00 +4.6%N/A0.3 $0.93 8/14/2020735,600 shares $787,092.00 -59.8%N/A0.2 $1.07 7/31/20201,830,000 shares $2.36 million +28.0%N/A0.5 $1.29 7/15/20201,430,000 shares $1.70 million -56.1%N/A0.4 $1.19 6/30/20203,260,000 shares $3.68 million +242.3%N/A1.1 $1.13 6/15/2020952,300 shares $842,595.04 +10.0%N/A0.6 $0.88 5/29/2020865,500 shares $751,254.00 -33.4%N/A0.6 $0.87 5/15/20201,300,000 shares $1.05 million +9.2%N/A1.1 $0.81 4/30/20201,190,000 shares $1.09 million +92.7%N/A1.4 $0.92 4/15/2020617,500 shares $432,188.25 +13.8%N/A0.9 $0.70 3/31/2020542,800 shares $439,668.00 +31.1%2.5%0.7 $0.81 3/13/2020414,200 shares $281,656.00 -5.2%1.9%0.8 $0.68 2/28/2020436,900 shares $200,974.00 -64.8%2.0%0.7 $0.46 2/14/20201,240,000 shares $731,600.00 +10.7%6.6%2 $0.59 1/31/20201,120,000 shares $896,000.00 +13.4%7.4%2 $0.80 1/15/2020988,000 shares $1.02 million -21.0%6.6%2 $1.03 12/31/20191,250,000 shares $1.56 million +303.5%8.3%3.5 $1.25 CTXR Short Interest - Frequently Asked Questions What is Citius Pharmaceuticals' current short interest? Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 11,790,000 shares of CTXR short. Learn More on Citius Pharmaceuticals' current short interest. What is a good short interest ratio for Citius Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTXR shares currently have a short interest ratio of 10.0. Learn More on Citius Pharmaceuticals's short interest ratio. Is Citius Pharmaceuticals' short interest increasing or decreasing? Citius Pharmaceuticals saw a drop in short interest during the month of October. As of October 31st, there was short interest totaling 11,790,000 shares, a drop of 5.1% from the previous total of 12,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Citius Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Citius Pharmaceuticals: Vistagen Therapeutics, Inc. (2.11%), Daré Bioscience, Inc. (0.35%), Biomea Fusion, Inc. (30.19%), Atea Pharmaceuticals, Inc. (3.50%), Mersana Therapeutics, Inc. (7.99%), UroGen Pharma Ltd. (28.14%), ADC Therapeutics SA (3.28%), Zentalis Pharmaceuticals, Inc. (9.89%), Fate Therapeutics, Inc. (13.96%), Lexeo Therapeutics, Inc. (9.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Citius Pharmaceuticals stock? Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Citius Pharmaceuticals? A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further. How often is Citius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Vistagen Therapeutics Short Interest Data Daré Bioscience Short Interest Data Biomea Fusion Short Interest Data Atea Pharmaceuticals Short Interest Data Mersana Therapeutics Short Interest Data UroGen Pharma Short Interest Data ADC Therapeutics Short Interest Data Zentalis Pharmaceuticals Short Interest Data Fate Therapeutics Short Interest Data Lexeo Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTXR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts